MASSY, France--(BUSINESS WIRE)--MITEM PHARMA, the pharmaceutical laboratory based in France and dedicated to Medicines of Major Therapeutic Interest (M.I.T.M.), is pleased to announce the worldwide acquisition of DESFERAL®, a major MITM in hematology, from Novartis (Basel - Switzerland).

法国马西——（商业新闻短讯）——MITEM PHARMA是一家总部位于法国的制药实验室，致力于主要治疗药物（M.I.T.M.），它很高兴地宣布从诺华（瑞士巴塞尔）全球收购血液学主要MITM DESFERAL®。

DESFERAL® (deferoxamine) is an injectable medicine indicated for the treatment of iron overload, which may occur for example following blood transfusions necessary for the treatment of beta-thalassaemia and sickle-cell anaemia. Deferoxamine is included in the WHO list of essential medicines.

DESFERAL®（去铁胺）是一种可注射药物，用于治疗铁超负荷，例如在治疗β地中海贫血和镰状细胞贫血所需的输血后可能发生铁超负荷。去铁胺被列入世卫组织基本药物清单。

The financing of this acquisition was made possible by the support of the historical partner TechLife Capital, MACSF and the funds managed by Access Capital Partners and Swen Capital Partners. These financial partners were motivated by the service provided to patients by MITMs, and the unique positioning of MITEM PHARMA dedicated to MITMs.

通过历史合作伙伴TechLife Capital、MACSF以及Access Capital Partners和Swen Capital Partners管理的资金的支持，本次收购的融资成为可能。这些财务合作伙伴的动机是MITMs为患者提供的服务，以及MITEM PHARMA致力于MITMs的独特定位。

The financial details of this transaction are not disclosed..

该交易的财务细节未披露。。

MITEM PHARMA is a new-generation pharmaceutical laboratory whose mission is to maintain and rejuvenate the range of treatments available for serious diseases. MITEM PHARMA identifies therapeutic needs, secures the supply and availability of existing medical need medicines in the market, and develops new products to ensure the availability of the best possible treatment for a targeted therapy..

MITEM PHARMA是新一代制药实验室，其使命是维持和振兴可用于严重疾病的治疗范围。MITEM PHARMA确定治疗需求，确保市场上现有医疗需求药物的供应和可用性，并开发新产品以确保为靶向治疗提供最佳治疗。。

DESFERAL® is now marketed in over 60 countries. It is manufactured in Europe. Its injectable (subcutaneous) formulation offers a well-known safety profile and extensive experience in medical protocols.

DESFERAL®现已在60多个国家销售。它是在欧洲制造的。其可注射（皮下）制剂具有众所周知的安全性和丰富的医疗方案经验。

Beta-thalassaemia is a hereditary disease affecting the quality of haemoglobin production, while sickle cell anaemia results from abnormal maturation of red blood cells. Both diseases result in tissue oxygenation defects and serious vascular disorders. An estimated 50 million people worldwide suffer from sickle cell anaemia, with 310,000 births affected each year.

β地中海贫血是一种影响血红蛋白产生质量的遗传性疾病，而镰状细胞贫血是由红细胞异常成熟引起的。这两种疾病都会导致组织氧合缺陷和严重的血管疾病。据估计，全世界有5000万人患有镰状细胞贫血，每年有310000名新生儿受到影响。

Beta-thalassaemia affects around 10 people per million population..

β地中海贫血影响每百万人口中约10人。。

With this acquisition, which will complement its existing portfolio of 4 MITMs, MITEM PHARMA has taken an important step in its growth strategy to create a major player dedicated to MITMs.

此次收购将补充其现有的4家MITM投资组合，MITEM PHARMA在其增长战略中迈出了重要一步，创建了一家专注于MITM的主要参与者。

Claude-Alain CUDENNEC and Eric THIERRY, founders of MITEM PHARMA, declare: 'We are proud to have completed this acquisition, which reflects in every way our determination to take action for hereditary diseases and rare diseases. The confidence that Novartis has shown in us through this sale is also recognition of the professionalism of all MITEM PHARMA's employees.

MITEM PHARMA的创始人Claude Alain CUDENNEC和Eric THIERRY宣布：“我们为完成此次收购感到骄傲，这从各个方面反映了我们对遗传性疾病和罕见疾病采取行动的决心。诺华通过此次销售在我们身上表现出的信心，也是对所有MITEM PHARMA员工专业精神的认可。

This step reinforces our objective of international growth and our commitment to securing the availability of MITMs in the most effective ways to patients.”.

这一步强化了我们的国际增长目标，以及我们以最有效的方式确保患者获得MITM的承诺。”。

Jacques ROSSIGNOL and Jean-Max DEMIAUTTE of TECHLIFE CAPITAL comment: 'We are pleased to accompany MITEM PHARMA in its strategic focus on developing and securing MITMs. We are honored to follow-on the great heritage from Novartis in the management of this important drug with proven efficacy in these severe diseases, DESFERAL®, which we plan to further develop and expand.

TECHLIFE CAPITAL的雅克·罗西诺尔（JacquesRossignol）和让·马克斯·德米奥特（JeanMax DEMIAUTTE）评论道：“我们很高兴能与MITEM PHARMA一起将战略重点放在开发和保护MITM上。我们很荣幸继承诺华在管理这种重要药物方面的伟大遗产，这种药物在这些严重疾病中已被证明有效，我们计划进一步开发和扩大DESFERAL®。

This acquisition will perfectly complement MITEM PHARMA’s existing portfolio of MITMs and will contribute to strengthening and enlarging its worldwide reach and presence.'.

此次收购将完美补充MITEM PHARMA现有的MITM投资组合，并将有助于加强和扩大其全球影响力和存在。”。

Sébastien COUVET, Financial Portfolio Manager at MACSF, explains: “MACSF, which wants to contribute to improving healthcare through its investments, supports the development of MITEM PHARMA. This pharmaceutical laboratory, which takes up and relaunches important drugs with proven efficacy in serious diseases, and secures their availability at reasonable prices, is useful to both patients and healthcare professionals.”.

MACSF财务投资组合经理Sébastien COUVET解释说：“MACSF希望通过其投资为改善医疗保健做出贡献，支持MITEM PHARMA的发展。该制药实验室负责研究并重新推出对严重疾病有效的重要药物，并以合理的价格确保其可用性，对患者和医疗保健专业人员都很有用。”。

About MITEM PHARMA

关于MITEM PHARMA

MITEM PHARMA is a French pharmaceutical laboratory specializing in Medicines of Major Therapeutic Interest (MITM). MITEM PHARMA's mission is to improve patients' quality of life by securing the availability of important drugs, the only treatments for severe diseases, whose supply shortages pose a public health risk.

MITEM PHARMA是一家法国制药实验室，专门从事主要治疗药物（MITM）。MITEM PHARMA的使命是通过确保重要药物的可用性来改善患者的生活质量，这些药物是治疗严重疾病的唯一方法，这些疾病的供应短缺会带来公共健康风险。

Working with partner doctors and patient associations, the company identifies these situations, and buys, upgrades, improves or develops these essential drugs to guarantee access to appropriate care. MITEM PHARMA constantly adapts to patients, the environment and market trends to make MITMs accessible at every stage of life, particularly in the fields of hematology, endocrinology, emergency cardiology and medical dermatology.

该公司与合作医生和患者协会合作，确定这些情况，并购买、升级、改进或开发这些基本药物，以确保获得适当的护理。MITEM PHARMA不断适应患者、环境和市场趋势，使MITM在生命的每个阶段都可以使用，特别是在血液学、内分泌学、急诊心脏病学和医学皮肤病学领域。

MITEM PHARMA is currently present in 15 countries on 3 continents..

MITEM PHARMA目前在三大洲的15个国家拥有业务。。

For further information: www.MITEMPHARMA.com

更多信息：www.MITEMPHARMA.com

About TECHLIFE CAPITAL

关于TECHLIFE CAPITAL

TECHLIFE CAPITAL is a growth equity fund specialising in the healthcare and technology industries, where it proactively identifies promising sector verticals that it investigates in depth (drugs of major therapeutic interest, cancer diagnostics, biotech services, orthopaedic prostheses, healthcare data management, etc.).

TECHLIFE CAPITAL是一家专注于医疗保健和技术行业的成长型股票基金，在该基金中，它积极识别其深入调查的有前途的垂直行业（主要治疗兴趣的药物、癌症诊断、生物技术服务、整形外科假体、医疗保健数据管理等）。

It then helps to structure these sectors by selecting and supporting ambitious companies in their transformation into European or even global leaders. TECHLIFE CAPITAL is currently invested in 8 companies in healthcare, health tech, and technologies. TECHLIFE CAPITAL SAS is a management company approved by the French Autorité des Marchés Financiers, and has been awarded the Tibi label for Innovation Financing by the French Ministry of the Economy..

然后，它通过选择和支持雄心勃勃的公司转型为欧洲甚至全球领导者，帮助构建这些部门。TECHLIFE CAPITAL目前投资于医疗保健、健康技术和技术领域的8家公司。。。

More information can be found on www.techlifecapital.com

更多信息请访问www.techlifecapital.com